A visualization of the cardio-pulmonary system [Adobe Stock]
Pulmonary arterial hypertension (PAH) is a relatively rare disorder, affecting roughly 15 to 50 people per million within the U.S. and Europe. Treating it with a single therapy can be challenging, and medication adherence often presents a common hurdle for the condition. Combination therapy has thus become a widely used option in the treatment of the condition, as the American Journal of Cardiovascular Drugs noted in 2018. The 2022 guidelines from the European Respiratory Society and European Society for Cardiology (ERS/ESC) further support the combination approach, emphasizing the importance of initial combination therapy in personalized PAH treatment strategies. The promise of a macitentan-tadalafil polypillHighlighted in The Journal of the American College of Cardiology, the DUE study focused on a once-daily, single-tablet combination of macitentan…